Citrates Monograph for Professionals - Drugs.com

Skip to main content
Print

# Citrates

Brand names: Bicitra, Cytra-2, Cytra-3, Cytra-K, Oracit
Drug class: Alkalinizing Agents
VA class: TN400
CAS number: 77-92-9

## Introduction

Alkalinizing agents.

## Uses for Citrates

Preparations containing sodium citrate and citric acid are especially useful when administration of potassium salts is undesirable or contraindicated, while those containing potassium citrate and citric acid are used when administration of sodium salts is undesirable or contraindicated.

### Alkalinization of Urine

Citrates are used for alkalinization of urine (as alternatives to sodium bicarbonate) in conditions where long-term maintenance of an alkaline urine is desirable (e.g., management of uric acid and cystine calculi of the urinary tract).

### Chronic Metabolic Acidosis

Citrates are used for management of chronic metabolic acidosis associated with conditions such as chronic renal insufficiency or renal tubular acidosis.

### Adjuvant in Gout Therapy

Citrates are used as adjuvants to uricosuric agents in gout therapy.

### Prevention of Milk Curdling

Sodium citrate has been used to alter cow’s milk so that large hard curds are not formed in the stomach of feeding infants† [off-label].

### Gastric Acid Neutralization

Some citrate salts (e.g., sodium citrate and citric acid) also used for buffering and neutralizing gastric hydrochloric acid.

### Compounding Uses

Sodium citrate and citric acid may be used as a buffer to maintain an approximate pH in various extemporaneous formulations. (See Compatibility under Stability.)

## Citrates Dosage and Administration

### General

- Selection of a specific preparation may in part be determined by potassium and sodium content.

- Unlike sodium bicarbonate solution, citrate solutions generally are considered highly palatable and pleasant tasting, and may be particularly useful as alkalinizing agents in patients who do not tolerate the taste of sodium bicarbonate oral solution.

### Administration

#### Oral Administration

Dilute oral citrate solutions with adequate amounts of water prior to administration to minimize the risk of GI complications, and follow with additional water after administration; enhance palatability by chilling the solution before administration.

Reconstitute contents of single-dose packets containing potassium citrate and citric acid for oral solution with cool water or juice prior to administration; give additional water or juice after administration.

Administer oral citrate solutions after meals to avoid the saline laxative effect of the drugs as well as upset stomach.

Shake oral solutions well before use, unless otherwise directed.

##### Reconstitution

Reconstitute contents of single-dose packets containing potassium citrate and citric acid for oral solution with at least 180 mL of cool water or juice prior to administration.

### Dosage

#### Pediatric Patients

##### General Pediatric Dosage

###### Potassium Citrate and Citric Acid

Oral

Usually, 5–15 mL of solution, diluted with 1/2 glass of water, after meals and at bedtime.

Do not use single-dose packets of potassium citrate and citric acid for oral solution in pediatric patients, since dosage for these patients can be more easily regulated with the commercially available oral solution. Individualize dosage according to the patient’s tolerance and response.

###### Sodium Citrate and Citric Acid

Oral

Children ≥2 years of age: Usually, 5–15 mL of solution, diluted in 30–90 mL of water, after meals and at bedtime; individualize dosage according to patient’s tolerance and response. Consult a clinician for use in children <2 years of age.

###### Tricitrates

Oral

Usually, 5–15 mL 4 times daily, after meals and at bedtime; individualize dosage according to patient’s tolerance and response.

##### Prevention of Milk Curdling

###### Sodium Citrate

Oral

Prevention of the formation of large curds in the stomach of feeding infants: Add 100 mg of sodium citrate to each 30 mL of cow’s milk.

#### Adults

##### General Adult Dosage

###### Potassium Citrate and Citric Acid

Oral

Usually, 15–30 mL of solution, diluted with 1 glass of water, after meals and at bedtime. The usual dosage of potassium citrate and citric acid for oral solution is one single-dose packet (containing 3300 mg of potassium citrate monohydrate and 1002 mg of citric acid monohydrate), reconstituted as directed 4 times daily, after meals and at bedtime. Individualize dosage according to patient’s tolerance and response.

###### Sodium Citrate

Oral

Usually, 1–2 g every 2–4 hours as necessary for alkalinization effect.

###### Sodium Citrate and Citric Acid

Oral

Usually, 10–30 mL of solution, diluted in 30–90 mL of water, after meals and at bedtime. Individualize dosage according to patient’s tolerance and response.

###### Tricitrates

Oral

Usually, 15–30 mL of solution diluted in water 4 times daily, after meals and at bedtime. Individualize dosage according to the patient’s tolerance and response.

##### Gastric Acid Neutralization

###### Sodium Citrate and Citric Acid

Oral

15 mL of solution, diluted in 15 mL of water, taken as a single dose.

## Cautions for Citrates

### Contraindications

- Potassium citrate and citric acid (oral solution and for oral solution [Cytra-K Crystals]): Manufacturer states that preparation is contraindicated in severe renal impairment with oliguria or azotemia, untreated Addison’s disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, or hyperkalemia (from any cause).

- Sodium citrate and citric acid oral solution (Bicitra, Cytra-2): Manufacturers state that preparations are contraindicated in patients requiring sodium-restricted diet and those with severe renal impairment.

- Sodium citrate and citric acid (Oracit): Manufacturer states that preparation is contraindicated in severe renal impairment, oliguria or azotemia, untreated Addison’s disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.

- Tricitrates oral solution (e.g., Cytra-3): Manufacturer states that preparation is contraindicated in severe renal impairment with oliguria and azotemia, untreated Addison’s disease, and severe myocardial damage.

### Warnings/Precautions

#### Warnings

##### Electrolyte and Acid-Base Disturbances

Potassium-containing formulations: Large doses may cause hyperkalemia and alkalosis, especially in patients with renal impairment. Listlessness, weakness, mental confusion, and tingling of the extremities may be associated with hyperkalemia.

Sodium-containing formulations: Excessive doses may cause metabolic alkalosis, especially in patients with hypocalcemia or renal impairment. Possible tetany or depression of the heart associated with decreased ionized calcium concentrations may occur with large doses.

#### General Precautions

##### Concomitant Disease

Sodium-containing formulations: Use with extreme caution in patients with low urine output (unless patient is closely supervised), CHF, hypertension, renal dysfunction, peripheral or pulmonary edema, or toxemia of pregnancy.

Potassium-containing formulations: Use with extreme caution in patients in whom excessive potassium may cause deleterious effects.

##### Adequate Patient Evaluation and Monitoring

Evaluate patient’s clinical condition and monitor serum electrolyte concentrations and acid-base balance periodically, especially in patients with renal impairment, to avoid complications.

##### Laxative Effects

Possible saline laxative effects; dilute citrate solution with water and administer after meals to minimize this effect.

#### Specific Populations

##### Pregnancy

Potassium citrate: Category A.

##### Lactation

Not known whether potassium citrate is distributed into milk. Because potassium freely distributes into and out of milk, use of potassium citrate by nursing woman with normal plasma potassium concentrations should have no adverse effect on nursing infant; milk potassium concentrations may be increased in hyperkalemic women.

##### Renal Impairment

Use citrates with caution in patients with renal impairment. Monitor serum electrolyte concentrations and acid-base balance to avoid complications (see Warnings/Precautions under Cautions). Manufacturers state that citrates are contraindicated in patients with severe renal impairment (see Contraindications under Cautions).

### Common Adverse Effects

Generally well tolerated at recommended dosages in patients with normal renal function and urine output. (See Warnings under Cautions.)

## Interactions for Citrates

### Specific Drugs

Drug | Interaction | Comments
--- | --- | ---
ACE inhibitors | Potential for hyperkalemia and toxicity with citrate preparations containing potassium |
Amphetamines | Urinary alkalinization may decrease renal elimination of amphetamines | Avoid concomitant use, especially in amphetamine overdosage
Antacids (aluminum-containing) | Increased GI absorption of aluminum; risk of aluminum toxicity in patients with chronic kidney disease receiving citrates and aluminum-containing drugs | Avoid concomitant use in patients with chronic kidney disease; sodium bicarbonate may be an alternative if aluminum-containing phosphate binders required
Cardiac glycosides | Potential for toxicity |
Chlorpropamide | Urinary alkalinization may increase renal elimination of chlorpropamide |
Diuretics, potassium-sparing | Potential for hyperkalemia and toxicity with citrate preparations containing potassium |
Eplerenone | Potential for hyperkalemia and toxicity with citrate preparations containing potassium |
Lithium | Urinary alkalinization may increase renal lithium clearance |
Potassium-containing drugs | Potential for hyperkalemia and toxicity with citrate preparations containing potassium |
Pseudoephedrine | Urinary alkalinization may decrease elimination of pseudoephedrine | Pseudoephedrine dosage reduction may be needed
Quinidine | Urinary alkalinization may decrease elimination of quinidine | Monitor ECGs and serum quinidine concentrations if citrate therapy is initiated or discontinued in a patient receiving a stable quinidine dosage
Salicylates | Urinary alkalinization may increase renal elimination of salicylates; possible decreased therapeutic and toxic effects of salicylates |

## Citrates Pharmacokinetics

### Distribution

#### Extent

Not known whether potassium citrate is distributed into milk.

### Elimination

#### Metabolism

Metabolism of citrates appears to be associated with bicarbonate formation.

#### Elimination Route

Citrates are excreted in urine, mainly as metabolites; <5% of an oral dose is excreted in the urine unchanged.

## Stability

### Storage

#### Oral

##### Solution

Potassium citrate and citric acid oral solutions (e.g., Cytra-K): Tight, light-resistant containers at 20–25°C; protect from excessive heat or freezing.

Potassium citrate and citric acid for oral solution (Cytra-K Crystals): Protect from excessive heat or freezing.

Sodium citrate and citric acid oral solution (Oracit): Well-closed containers at 15–30°C.

Sodium citrate and citric acid oral solution (Cytra-2): Tight, light-resistant containers at 20–25°C; protect from freezing.

Sodium citrate and citric acid oral solution (Bicitra): Tight containers; protect from freezing or excessive heat.

Tricitrates oral solution (e.g., Cytra-3): Tight, light-resistant containers at 20–25°C; protect from excessive heat or freezing.

### Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

#### Oral

##### Solution

May use sodium citrate and citric acid as a buffer to maintain an approximate pH in various extemporaneous formulations. In general, the addition of the following concentration of the drugs should produce a solution buffered to the approximate pH listed:

Adapted from Schumacher GE. Buffer formulations. Am J Hosp Pharm. 1966; 23:628-9.

Citrate Buffer
pH | Citric Acid Monohydrate g/L | Sodium Citrate Dihydrate g/L
--- | --- | ---
2.5 | 64.4 | 7.8
3.0 | 57.4 | 17.6
3.5 | 47.6 | 31.4
4.0 | 40.6 | 41.2
4.5 | 30.8 | 54.9
5.0 | 19.6 | 70.6
5.5 | 9.8 | 84.3
6.0 | 4.2 | 92.1
6.5 | 1.8 | 95.6

## Actions

- Potassium citrate is absorbed and then appears to be metabolized to potassium bicarbonate, resulting in systemic alkalinization.

- Sodium citrate is absorbed and then appears to be metabolized to sodium bicarbonate, resulting in systemic alkalinization.

- Sodium citrate has anticoagulant activity; prevents the clotting of blood by forming an undissociated calcium citrate complex, making calcium unavailable to the clotting mechanism. Anticoagulant sodium citrate solution, when added to blood, prevents the clotting of blood and the crenation or swelling of cells. Sterile solution is used as an anticoagulant for banked blood for transfusion and to prepare citrated human plasma and blood for fractionation.

- Sodium citrate prevents the curdling of milk by rennin; has been used to alter cow’s milk so that large hard curds are not formed in the stomach of feeding infants.

## Advice to Patients

- Importance of following instructions for dosage preparation, including reconstitution and/or dilution recommendations. (See Oral Administration under Dosage and Administration.)

- Importance of taking drugs only as prescribed, unless otherwise instructed by a clinician.

- Importance of taking doses after meals to avoid saline laxative effect.

- Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.

- Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.

- Importance of informing patients of other important precautionary information. (See Cautions.)

## Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Potassium Citrate and Citric Acid
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | For solution | Potassium Citrate Monohydrate 3300 mg and Citric Acid Monohydrate 1002 mg per packet | Cytra-K Crystals | Cypress
| Solution | Potassium Citrate Monohydrate 1100 mg/5 mL and Citric Acid Monohydrate 334 mg/5 mL* | Cytra-K | Cypress
|  |  | Potassium Citrate Monohydrate and Citric Acid Monohydrate Solution |

Sodium Citrate
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Bulk | Powder |  |  |

Sodium Citrate and Citric Acid
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | Solution (Shohl’s Solution) | Hydrous Sodium Citrate 490 mg/5 mL and Citric Acid 640 mg/5 mL | Oracit | Carolina Medical
|  | Sodium Citrate Dihydrate 500 mg/5 mL and Citric Acid Monohydrate 334 mg/5 mL | Bicitra | Ortho-McNeil
|  |  | Cytra-2 | Cypress

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Tricitrates
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer
--- | --- | --- | --- | ---
Oral | Solution | Citric Acid Monohydrate 334 mg/5 mL, Potassium Citrate Monohydrate 550 mg/5 mL, and Sodium Citrate Dihydrate 500 mg/5 mL* | Cytra-3 Syrup | Cypress
|  |  | Citric Acid Monohydrate, Potassium Citrate Monohydrate, and Sodium Citrate Dihydrate Solution |

AHFS DI Essentials™. © Copyright 2023, Selected Revisions April 1, 2009. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

Reload page with references included

Medical Disclaimer